

ANSWERS TO ESTIMATES QUESTIONS ON NOTICE

HEALTH AND AGEING PORTFOLIO

Supplementary Budget Estimates 2011-2012, 19 October 2011

Question: E11-283

OUTCOME 1: Population Health

Topic: CSL PRODUCTS

Written Question on Notice

Senator Fierravanti-Wells asked:

What CSL products are currently on the National Immunisation Program?

Answer:

As provided in the National Health (Immunisation Program – Designated Vaccines) Determination 2011(No.2).

The following vaccines, manufactured or imported by CSL, are listed for use under the National Immunisation Program.

<u>Brand</u>	<u>Vaccine against</u>
Pedvax	Haemophilus influenzae type b (Hib) (monovalent PRP-OMP)
Menjugate	Meningococcal C (conjugate)
Pneumovax 23	Pneumococcal (polysaccharide, 23-valent)
Q-Vax	Q fever
VAQTA Paediatric/Adolescent	Hepatitis A (monovalent)
H-B-Vax II	Hepatitis B (monovalent adult)
H-B-Vax II	Hepatitis B (monovalent paediatric)
Fluvax <sup>®</sup>	Influenza
Fluvax <sup>®</sup> Junior	Influenza
Varivax Refrigerated	Varicella
Gardasil	Human Papillomavirus (HPV)
Rotateq	Rotavirus
Comvax	Hepatitis B and Haemophilus influenza type b (Hib)

Although CSL influenza vaccine *Fluvax<sup>®</sup> Junior* is listed on the Determination, CSL's vaccine *Fluvax<sup>®</sup>*, including *Fluvax<sup>®</sup> Junior* are not currently registered for use in Australia for children under five years of age. In 2011, the Australian Technical Advisory Group on Immunisation (ATAGI) recommended, and the Chief Medical Officer endorsed, that *Fluvax<sup>®</sup>* only be used in children aged five years to less than 10 years of age when no alternative influenza vaccine is readily available.